Centessa Pharmaceuticals (CNTA)
(Delayed Data from NSDQ)
$16.58 USD
+0.73 (4.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $16.25 -0.33 (-1.99%) 4:50 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CNTA 16.58 +0.73(4.61%)
Will CNTA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CNTA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTA
Are Medical Stocks Lagging Stryker (SYK) This Year?
Wall Street Analysts Believe Centessa Pharmaceuticals (CNTA) Could Rally 48.85%: Here's is How to Trade
CNTA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Down -10.98% in 4 Weeks, Here's Why You Should You Buy the Dip in Centessa Pharmaceuticals (CNTA)
The Zacks Analyst Blog Highlights Amphastar Pharmaceuticals, Journey Medical, Centessa Pharmaceuticals and Aquestive Therapeutics
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
Other News for CNTA
Centessa Pharmaceuticals rises after upgrade to Overweight at Morgan Stanley
Morgan Stanley gets more bullish on Centessa, upgrades shares
Morgan Stanley upgrades Centessa on 'best-in-class' potential of ORX750
Centessa initiated with bullish view at B. Riley, here's why
Centessa Pharmaceuticals a new buy at B Riley on sleep disorders pipeline